Article
Gastroenterology & Hepatology
Stefan Schreiber, Shomron Ben-Horin, Jaroslaw Leszczyszyn, Robert Dudkowiak, Adi Lahat, Beata Gawdis-Wojnarska, Aldis Pukitis, Marek Horynski, Katalin Farkas, Jaroslaw Kierkus, Maciej Kowalski, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Mi Rim Kim, Seul Gi Lee, Byong Duk Ye, Walter Reinisch
Summary: This study demonstrated the pharmacokinetic noninferiority of CT-P13 SC to CT-P13 IV, with comparable clinical remission rates between the two formulations.
Article
Multidisciplinary Sciences
Ruize Liu, Dalin Li, Talin Haritunians, Yunfeng Ruan, Mark J. Daly, Hailiang Huang, Dermot P. B. McGovern
Summary: This study presents a novel molecular-based prediction model that combines genetics, serum biomarkers, and smoking information to assist in the diagnosis of Crohn's disease and ulcerative colitis. The joint model explains approximately 46% of phenotypic variation, with genetics making unique contributions to distinguishing disease subtypes and smoking status potentially not being an effective biomarker.
Review
Medicine, Research & Experimental
Yu Chen, Guolin Zhang, Yuewen Yang, Shuangshuang Zhang, Haozheng Jiang, Kang Tian, Arenbaoligao, Dapeng Chen
Summary: Crohn's disease and ulcerative colitis, as chronic autoimmune diseases, are rapidly increasing in incidence in Asia. Monoclonal antibodies (mAbs) have shown promising effects in treating IBD, particularly moderate-to-severe CD and UC, by targeting inflammatory pathways. This review comprehensively summarizes the clinical reports and studies on the use of mAbs in IBD treatment in Asian countries, highlighting the current status and differences with the West.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Gastroenterology & Hepatology
Anthony Buisson, Maria Nachury, Maud Reymond, Clara Yzet, Pauline Wils, Laure Payen, Marie Laugie, Luc Manlay, Nicolas Mathieu, Bruno Pereira, Mathurin Fumery
Summary: This study assessed the effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases (IBDs). The results showed that switching from intravenous to subcutaneous infliximab was safe and well accepted, with a low risk of relapse in IBD patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Camilla de Almeida Martins, Matheus Freitas Cardoso de Azevedo, Alexandre Sousa Carlos, Aderson Omar Mourao Cintra Damiao, Carlos Walter Sobrado Jr, Sergio Carlos Nahas, Natalia Sousa Freitas Queiroz
Summary: This study has enhanced our understanding of the predictive factors of treatment response to IFX in a well-characterized Brazilian IBD population. The study found that the duration of IFX therapy and higher albumin levels increased the likelihood of clinical remission, while previous surgery decreased its chance. Prior use of adalimumab and higher C-reactive protein levels reduced the likelihood of endoscopic remission.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Miikka Hoyhtya, Katri Korpela, Schahzad Saqib, Sofia Junkkari, Eija Nissila, Anne Nikkonen, Evgenia Dikareva, Anne Salonen, Willem M. de Vos, Kaija-Leena Kolho
Summary: This study aimed to investigate the absolute abundances of gut microbiota in relation to the response to induction therapy with infliximab in pediatric inflammatory bowel disease. The results showed that the treatment responsive group had a higher absolute abundance of Bifidobacteriales and a lower absolute abundance of Actinomycetales compared to the nonresponders. However, the level of inflammation according to fecal calprotectin showed no statistically significant association with the absolute abundances of fecal microbiota. The results on relative abundances differed from the absolute abundances.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Biochemistry & Molecular Biology
Vishal Khatri, Ramaswamy Kalyanasundaram
Summary: This review focuses on the association between IBD and gut inflammasome, as well as recent advances in research and therapeutic strategies for IBD, discussing inflammasomes and their components, outcomes from experimental animals and human studies, inflammasome inhibitors, and developments in inflammasome-targeted therapies for IBD.
Review
Biochemistry & Molecular Biology
HyunTaek Jung, Jae Seok Kim, Keum Hwa Lee, Kalthoum Tizaoui, Salvatore Terrazzino, Sarah Cargnin, Lee Smith, Ai Koyanagi, Louis Jacob, Han Li, Sung Hwi Hong, Dong Keon Yon, Seung Won Lee, Min Seo Kim, Paul Wasuwanich, Wikrom Karnsakul, Jae Il Shin, Andreas Kronbichler
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract that mainly affects young people. Recent studies have shown that microRNAs (miRNAs) play an important role in the pathogenesis, diagnosis, and treatment of IBD.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Uma Mahadevan, Millie D. Long, Sunanda Kane, Abhik Roy, Marla C. Dubinsky, Bruce E. Sands, Russell D. Cohen, Christina D. Chambers, William J. Sandborn
Summary: The study found that exposure to biologic, thiopurine, or combination therapy during pregnancy did not increase adverse maternal or fetal outcomes, and these treatments can be continued throughout pregnancy for women with IBD to maintain disease control.
Article
Medicine, General & Internal
Silvia Salvatori, Francesco Baldassarre, Michelangela Mossa, Giovanni Monteleone
Summary: Long COVID is common in patients with inflammatory bowel diseases (IBD), with fatigue being the most frequent symptom. It does not influence the frequency of IBD relapses, but is more prevalent in female patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Jurij Hanzel, Laura H. Bukkems, Krisztina B. Gecse, Geert R. D'Haens, Ron A. A. Mathot
Summary: The study characterized the pharmacokinetics of subcutaneous CT-P13 through population PK modeling, identifying body weight, presence of anti-drug antibodies, and serum albumin concentration as clinically relevant covariates affecting drug clearance. Simulated drug exposure demonstrated differences between routes of administration in patients of varying body weights.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Gastroenterology & Hepatology
Thomas M. Goodsall, Tran M. Nguyen, Claire E. Parker, Christopher Ma, Jane M. Andrews, Vipul Jairath, Robert Bryant
Summary: The study systematically identified ultrasound scoring indices for assessing inflammatory bowel disease activity, with common components including bowel wall thickness, colour Doppler imaging, and bowel wall stratification. The correlation between ultrasound indices and reference standards, as well as sensitivity, specificity, accuracy, and other properties, varied within certain ranges. However, reliability and responsiveness data were limited, and most studies were rated with unclear or high risk of bias.
JOURNAL OF CROHNS & COLITIS
(2021)
Review
Medicine, General & Internal
Katarzyna Akutko, Andrzej Stawarski
Summary: Inflammatory bowel diseases (IBD) are chronic inflammatory diseases of the digestive tract with periods of remission and relapses. The etiopathogenesis is not fully understood, leading to only symptomatic treatment. There is a constant need to search for new high safety profile therapies for IBD.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Biotechnology & Applied Microbiology
Guihua Chen, Jun Shen
Summary: Inflammatory bowel disease (IBD) is a global disease with high morbidity and medical costs. Early diagnosis and intervention are crucial for controlling its progression.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2021)
Article
Gastroenterology & Hepatology
Thomas X. Lu, Matthew Dapas, Erika Lin, Trevor Peters, Atsushi Sakuraba
Summary: In this meta-analysis of randomized controlled studies, patients with IBD who took PPIs were less likely to achieve remission while on infliximab therapy. Further investigation into the effect of PPIs on IBD outcomes and therapies is warranted based on our study's results.
Article
Rheumatology
Elisa Dalix, Mathieu Maalouf, Sylvie Peyroche, Arnaud Vanden-Bossche, Charles-Antoine Arthaud, Sophie Hodin, Ruediger B. Mueller, Hubert Marotte
Summary: In this study, the co-administration of MTX and FA in rat adjuvant-induced arthritis (AIA) was tested for its efficacy. The results showed that co-administration of MTX with FA on the same day did not reduce efficacy compared with FA application one day after MTX. This suggests that the combination of MTX and FA could be more convenient and improve compliance in patients.
Article
Gastroenterology & Hepatology
Mathurin Fumery, Stephane Nancey, Jerome Filippi, Romain Altwegg, Xavier Hebuterne, Gilles Boshetti, Mathilde Barraud, Jonathan Meynier, Stephane Paul, Xavier Roblin
Summary: This study evaluated the effectiveness and safety of golimumab intensification and identified the best threshold of serum golimumab before drug intensification. The results showed that after golimumab intensification, 40% of patients experienced clinical response, 10% experienced clinical remission, 33% experienced endoscopic response, and 23% experienced endoscopic remission.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Microbiology
Beatriz Miguelena Chamorro, Karelle De Luca, Gokul Swaminathan, Stephanie Longet, Egbert Mundt, Stephane Paul
Summary: Bordetella pertussis and Bordetella bronchiseptica are responsible for whooping cough in humans and chronic cough in dogs, respectively. Both can evade host immune responses, but this ability is more pronounced in B. bronchiseptica. Collaborative efforts between veterinary and human medical fields are essential to control these infections.
CLINICAL MICROBIOLOGY REVIEWS
(2023)
Article
Medicine, General & Internal
Xavier Roblin, Gerard Duru, Konstantinos Papamichael, Adam S. Cheifetz, Sandy Kwiatek, Anne-Emmanuelle Berger, Mathilde Barrau, Louis Waeckel, Stephane Nancey, Stephane Paul
Summary: Monitoring of anti-drug antibodies in patients on ustekinumab is not recommended due to low immunogenicity. This study aimed to investigate the relationship between anti-drug antibodies and loss of response to ustekinumab in patients with IBD. The results showed that ATU was an independent predictor of LOR to ustekinumab in IBD patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Immunology
Carla Saade, Bruno Pozzetto, Melyssa Yaugel-Novoa, Guy Oriol, Laurence Josset, Bruno Lina, Stephane Paul, Antonin Bal, Sophie Trouillet-Assant
Summary: This study examines the humoral immune response in vaccinated patients who are simultaneously infected with Delta and Omicron BA.1 variants of SARS-CoV-2. The findings indicate that exposure to both Delta and BA.1 S proteins does not provide an additional immune advantage compared to exposure to BA.1 S protein alone.
Article
Immunology
Melyssa Yaugel-Novoa, Blandine Noailly, Fabienne Jospin, Anne-Emmanuelle Berger, Louis Waeckel, Elisabeth Botelho-Nevers, Stephanie Longet, Thomas Bourlet, Stephane Paul
Summary: The study found that prior immunization did not increase the risk of SARS-CoV-2 infection in COVID-19 patients and vaccinated individuals. There was no enhanced infection effect observed in serum samples from COVID-19 patients with any tested viral variants (Delta and Omicron). Some serum samples from vaccinated individuals showed a mild IgA-ADE effect with Omicron after the completion of the full vaccination scheme, but this effect disappeared.
Article
Immunology
Beatriz Miguelena Chamorro, Karelle De Luca, Gokul Swaminathan, Nicolas Rochereau, Jade Majorel, Herve Poulet, Blandine Chanut, Lauriane Piney, Egbert Mundt, Stephane Paul
Summary: In this study, the immune responses and protection offered by a canine mucosal vaccine against Bordetella bronchiseptica were investigated using a rat model. The results showed that mucosal vaccination can induce mucosal immune responses and provide protection against a Bb challenge.
Article
Biochemistry & Molecular Biology
Tristan Gabriel-Segard, Jessica Rontard, Louise Miny, Louise Dubuisson, Aurelie Batut, Delphine Debis, Melanie Gleyzes, Fabien Francois, Florian Larramendy, Alessandra Soriano, Thibault Honegger, Stephane Paul
Summary: This study presents a microfluidic technology that models bilateral neuro-immunological communication, confirming the communication between dendritic cells and neurons in inflammatory conditions such as IBD. The platform can be used for pharmacological compound screening and may help improve patient outcomes by blocking the gut-brain axis at a mucosal level.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Letter
Rheumatology
Elodie Drumez, Christophe Richez, Louis Bebear, Muriel Herasse, Rene-Marc Flipo, Hubert Marotte, Sophie Georgin-Lavialle, Raphaele Seror, Edouard Pertuiset, Jerome Avouac, Pascal Chazerain, Nicolas Roux, Thao Pham, Emmanuelle Dernis, Yurdagul Uzunhan, Amelie Servettaz, Soumaya El Mahou, Patrice Cacoub, Mohamed Hamidou, Bruno Fautrel, Thierry Thomas, Eric Hachulla
Editorial Material
Gastroenterology & Hepatology
Xavier Roblin, Stephane Paul
JOURNAL OF CROHNS & COLITIS
(2023)
Editorial Material
Veterinary Sciences
Beatriz Miguelena Chamorro, Gokul Swaminathan, Egbert Mundt, Stephane Paul
Summary: Oral vaccines are convenient to administer and can activate mucosal immune responses. However, preclinical studies using gavage as a technique for oral vaccine administration have limitations. Alternative methods need to be explored.
Article
Rheumatology
Jean Escal, Tiphany Neel, Sophie Hodin, Karima Boussoualim, Adamah Amouzougan, Astrid Coassy, Herve Locrelle, Thierry Thomas, Xavier Delavenne, Hubert Marotte
Summary: This study aimed to identify a biomarker of MTX resistance (MTXR) by comparing differentially expressed blood proteins between patients with active RA and patients in remission after MTX treatment. Untargeted proteomics analysis revealed eight plasma proteins that were differentially expressed between the two groups, with triosephosphate isomerase (TPI-1) and glucose-6-phosphate isomerase (GPI) found down-regulated in the active group. This result was confirmed for TPI-1 in the targeted proteomics analysis.
Review
Health Care Sciences & Services
Vered Abitbol, Salim Benkhalifa, Caroline Habauzit, Hubert Marotte
Summary: This article explores the characteristics of various adalimumab biosimilars to help clinicians navigate the various options available across Europe and the USA. Effective patient-physician communication is also emphasized to nurture realistic patient expectations and minimize potential nocebo effects when prescribing biosimilars.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
(2023)
Review
Medicine, General & Internal
Mathilde Barrau, Xavier Roblin, Leslie Andromaque, Aurore Rozieres, Mathias Faure, Stephane Paul, Stephane Nancey
Summary: Data on the long-term effects of in utero drug exposure on childhood development are lacking, but therapeutic drug monitoring during pregnancy can help limit fetal drug exposure. The levels and duration of drug exposure impact the outcomes.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Xavier Roblin, Stephane Nancey, Konstantinos Papamichael, Gerard Duru, Mathurin Flamand, Sandy Kwiatek, Adam Cheifetz, Nicole Fabien, Mathilde Barrau, Stephane Paul
Summary: Higher concentrations of subcutaneous infliximab are associated with better therapeutic outcomes in patients with inflammatory bowel disease, especially deep remission.
JOURNAL OF CROHNS & COLITIS
(2023)